Hedge fund pressure is reshaping Kenvue Inc, with the consumer health giant announcing the ouster of CEO Thibaut Mongon and the launch of a broad strategic review – a clear win for activist investors Starboard Value, TOMS Capital, and Third Point.
Kirk Perry, a current board director, has been named interim CEO, effective immediately, as the company – spun out of Johnson & Johnson in 2023 ≠ responds to mounting hedge fund demands for operational and structural change.
The shake-up comes just months after Starboard CEO Jeffrey Smith joined Kenvue’s board, a move that averted a potential proxy battle. TOMS Capital has also publicly advocated for a full sale or asset divestitures, while Dan Loeb’s Third Point quietly built a position earlier this year, according to reports.
Monday’s announcement signals that activist hedge funds have gained serious leverage over Kenvue’s strategic direction. The board has retained Centerview Partners and McKinsey & Co to evaluate portfolio simplification and other transformational options.
Shares rose over 4% on the news, reflecting investor optimism that hedge fund influence could unlock value at the underperforming consumer brands firm.
The preliminary Q2 earnings report showed a 4% decline in net sales, missing estimates, further underscoring investor frustration with current execution and validating activist calls for change.
Mongon’s departure is classified as without cause, and he will receive severance.
